Immunotherapy definitely stops the spread of cancer in a quarter of patients

Paris – A clinical trial evaluating the effectiveness of cancer immunotherapy shows that this new therapeutic arsenal has maintained results achieved in an average of 25% of patients, according to the Cory Institute.
Immunotherapy, which stimulates the immune system to fight cancer cells, has contributed significantly to the development of cancer care in recent years. But in most cases, it is only useful in a few patients and its effect varies greatly depending on the type of disease.
"We have tried to determine the proportion of patients responding to a durable response to immunosuppressive therapy and compare," said researchers at the Cory Institute in Paris, who collaborated with colleagues at French research centers on cancer, in an article published in the journal JCO Prescien Oncoludge. Results with those of other types of drugs. "